NCT07112586

Brief Summary

Intradermal injection of exosomes in treatment of male androgenetic alopecia, clinically and using a immunohistochemical marker

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for phase_1

Timeline
9mo left

Started Aug 2025

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress48%
Aug 2025Jan 2027

First Submitted

Initial submission to the registry

August 1, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 8, 2025

Completed
22 days until next milestone

Study Start

First participant enrolled

August 30, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2026

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2027

Expected
Last Updated

August 8, 2025

Status Verified

August 1, 2025

Enrollment Period

5 months

First QC Date

August 1, 2025

Last Update Submit

August 1, 2025

Conditions

Androgenetic Alopecia

Keywords

Androgenetic Alopecia

Outcome Measures

Primary Outcomes (1)

  • Terminal to vellus hair ratio improvement

    Counting the terminal and vellus hair counts and calculating the ratio, and comparing it between different study sessions and at follow-ups

    One year

Study Arms (1)

Males 18-40 years old with androgenetic alopecia

EXPERIMENTAL

Males with androgenetic alopecia willing to do mesotherapy sessions

Drug: Plasma derived exosomes

Interventions

Plasma derived exosomesDRUG

Exosomes derived from patients' plasma, centrifuged at high speeds multiple times

Males 18-40 years old with androgenetic alopecia

Eligibility Criteria

Age18 Years - 40 Years
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsMales
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • \- Androgenetic Alopecia Grades 1-4

You may not qualify if:

  • blood diseases Receiving other treatments History of malignancy or allergic reaction to exosomes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain Shams Univeristy Faculty of medicine

Cairo, Abbasia, 11757, Egypt

Location

MeSH Terms

Conditions

Alopecia

Condition Hierarchy (Ancestors)

HypotrichosisHair DiseasesSkin DiseasesSkin and Connective Tissue DiseasesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Central Study Contacts

Dana Ashraf Maher, Assistant lecturer

CONTACT

+20 1225077011dana.maher1@outlook.com

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 1, 2025

First Posted

August 8, 2025

Study Start

August 30, 2025

Primary Completion

January 31, 2026

Study Completion (Estimated)

January 31, 2027

Last Updated

August 8, 2025

Record last verified: 2025-08

Locations

EG(1)